Sheba Pediatric CAR-T Program for Burkitt Lymphoma at JCI accreditated and Top-10 Hospitals 2025 by Newsweek Hospital
O que está incluído neste pacote
Procedimentos médicos
- Terapia com células T CAR
- 3 refeições por dia pelo nutricionista
- Serviços de enfermagem 24 horas
- Eletrocardiograma (ECG)
- Exames de sangue
- Radiografia do tórax
- Teste anti-HIV
- Teste anti-HBC
- Teste Anti-HCVAb
- Ecocardiografia
- Hemograma completo (HC)
- Exame de sangue para bioquímica
- Consulta com um oncologista
- Consulta com um hematologista
- Consulta com um imunologista
- Consulta com cardiologista
- Consulta com um hematologista pediátrico
- Consulta com um pediatra
- Consulta com um onco-hematologista
- Ressonância Magnética do Crânio
- Biópsia
- Hemograma completo com marcadores tumorais e proteinograma
Duração
- 20 dias no hospital
Acomodação
Hospitalização
Transporte
Transfer aeroporto-clínica-aeroporto
Informações adicionais
Sheba Pediatric CAR-T Program for Burkitt Lymphoma
At Sheba Medical Center, children and young patients with Burkitt lymphoma have access to one of the most advanced and trusted CAR-T therapy programs in the world. This highly aggressive form of lymphoma requires rapid, precise treatment, especially in relapsed or treatment-resistant cases where CAR-T therapy offers a powerful, personalized option.
A Personalized Treatment Designed for Each Child
CAR-T therapy uses the patient’s own immune system to recognize and eliminate cancer cells. For children with Burkitt lymphoma, this innovative approach can provide new hope when conventional therapies are no longer effective.
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality:
Apheresis – collection of the patient’s T-cells
Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target lymphoma
Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for durable remission.
Expert Pediatric Leadership and Care
The program is led by Prof. Amos Toren, a world-recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and more than 1,500 bone marrow transplants performed.
Children are cared for within a dedicated pediatric environment that includes:
Specialized pediatric CAR-T units with 24/7 monitoring
A multidisciplinary team of experts in hematology, oncology, and immunology
A family-centered approach, focused on comfort, safety, and support
Full international patient services, including travel and care coordination
Proven Expertise in Complex Cases
Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes:
~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults
The team has extensive experience treating high-risk and aggressive lymphomas, including Burkitt lymphoma, offering advanced options when other treatments have limited success.
Comprehensive Evaluation and Support
Each child undergoes a full diagnostic work-up before treatment, including:
advanced imaging, bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment.
Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire process.
A Trusted Place for Advanced Pediatric Cancer Care
By combining rapid access to treatment, leading medical expertise, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Burkitt lymphoma with CAR-T therapy focused on achieving remission and helping children return to a healthy and active life.
Assistência Bookimed 24/7
- Coordenador médico pessoal
- Arranjos de viagem médica — reserva de passagens aéreas e quartos de hotel com preços especiais de parceiros
- Defesa do paciente durante a viagem médica
Preço do programa
O que NÃO está incluído neste pacote
Médico
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Como estamos indo?
Sobre a clínica
A terapia com células CAR-T no Sheba Medical Center em Tel Aviv, Israel, pode custar cerca de US$ 63.100 pelo programa completo. O hospital está entre os 10 melhores do mundo e oferece este tratamento avançado sob a coordenação do Prof. Arnon Nagler, um renomado especialista em transplante de medula óssea.
Sobre o Tratamento
A terapia com células CAR-T é uma abordagem inovadora para leucemia, linfoma e mieloma múltiplo. O processo envolve a coleta das células T do paciente, sua modificação genética em laboratório e a reinfusão após a quimioterapia. O procedimento exige 21 dias de internação hospitalar, com possibilidade de permanência na UTI.
O que está incluído
- Avaliação abrangente (US$ 5.000 - US$ 10.000)
- Coleta de células via aférese (US$ 6.600)
- Preparação laboratorial das células modificadas (US$ 20.000)
- Quimioterapia de condicionamento (US$ 5.000)
- Internação de 21 dias (US$ 31.500)
- Avaliação pós-tratamento (US$ 3.000 - US$ 5.000)
Preparação e Recuperação
Os pacientes necessitam de biópsia de medula óssea, exames de PET/CT e exames de sangue antes do tratamento. Após a infusão, ocorre o monitoramento diário para a síndrome de liberação de citocinas. A permanência total recomendada em Israel é de 4 a 6 semanas. Vale ressaltar que o CAR-T para mieloma ainda é experimental.
O Sheba Medical Center atende 1,5 milhão de pacientes anualmente e oferece atendimento multilíngue. É necessário um depósito de US$ 50.000 a US$ 60.000 antes da chegada. Entre em contato com o hospital para avaliar se esta terapia é adequada para o seu caso.
Pagamento e Recompensas
Não pague por nossos serviços
Efetue o pagamento diretamente na clínica ou na conta bancária oficial dela.
Algumas clínicas podem exigir um depósito como parte de sua política.
Divida seus pagamentos com opções de parcelamento.
Ganhe recompensas por indicar amigos ao Bookimed.